Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2018

01-08-2018 | Gastrointestinal Oncology

Palliative Management of Peritoneal Metastases

Authors: Laura A. Lambert, Jason Wiseman

Published in: Annals of Surgical Oncology | Issue 8/2018

Login to get access

Abstract

Despite significant recent advances in the management of peritoneal carcinomatosis, this diagnosis still is accompanied frequently by a grim survival prognosis, often measured in weeks to months. The poor prognosis also is accompanied often by complications and symptoms that have a dramatic impact on quality of life and are challenging to the managing health care provider and devastating to loved ones caring for the person who is suffering. Consequently, management of carcinomatosis often revolves around palliation of symptoms such as bowel obstruction, nausea, pain, fatigue, and cachexia as well as emotional and existential concerns. This article reviews several palliative treatment options for some of the more common symptoms and complications associated with advanced, incurable peritoneal carcinomatosis. Although readers should recognize that carcinomatosis is no longer an imminent death sentence, providers caring for patients with peritoneal carcinomatosis also must be well-versed in the palliative management of this condition and recognize the utility of early palliative care referral in this setting.
Literature
1.
Paul Olson TJ, Pinkerton C, Brasel KJ, Schwarze ML. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review. JAMA Surg. 2014;149:383–92.CrossRefPubMedPubMedCentral
2.
3.
White JV, Guenter P, Jensen G, et al. Consensus statement: academy of nutrition and dietetics and American Society for parenteral and enteral nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J Parenter Enteral Nutr. 2012;36:275–83.CrossRefPubMed
4.
Mosler P, Mergener KD, Brandabur JJ, Schembre DB, Kozarek RA. Palliation of gastric outlet obstruction and proximal small bowel obstruction with self-expandable metal stents: a single-center series. J Clin Gastroenterol. 2005;39:124–8.PubMed
5.
Holt AP, Patel M, Ahmed MM. Palliation of patients with malignant gastroduodenal obstruction with self-expanding metallic stents: the treatment of choice? Gastrointest Endosc. 2004;60:1010–7.CrossRefPubMed
6.
7.
8.
Yoon JY, Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Clinical outcomes and risk factors for technical and clinical failures of self-expandable metal stent insertion for malignant colorectal obstruction. Gastrointest Endosc. 2011;74:858–68.CrossRefPubMed
9.
10.
Kim JH, Ku YS, Jeon TJ, et al. The efficacy of self-expanding metal stents for malignant colorectal obstruction by noncolonic malignancy with peritoneal carcinomatosis. Dis Colon Rectum. 2013;56:1228–32.CrossRefPubMed
11.
Caceres A, Zhou Q, Iasonos A, Gerdes H, Chi DS, Barakat RR. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol. 2008;108:482–5.CrossRefPubMed
12.
Pothuri B, Montemarano M, Gerardi M, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol. 2005;96:330–4.CrossRefPubMed
13.
Ryan JM, Hahn PF, Mueller PR. Performing radiologic gastrostomy or gastrojejunostomy in patients with malignant ascites. AJR Am J Roentgenol. 1998;171:1003–6.CrossRefPubMed
14.
Shaw C, Bassett RL, Fox PS, et al. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol. 2013;20:497–505.CrossRefPubMed
15.
Laval G, Marcelin-Benazech B, Guirimand F, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manage. 2014;48:75–91.CrossRefPubMed
16.
17.
Laval G, Rousselot H, Toussaint-Martel S, et al. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction. Bull Cancer. 2012;99:E1–9.PubMed
18.
Mariani P, Blumberg J, Landau A, et al. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2012;30:4337–43.CrossRefPubMed
19.
Narayanan P, Nobbenhuis M, Reynolds KM, Sahdev A, Reznek RH, Rockall AG. Fistulas in malignant gynecologic disease: etiology, imaging, and management. Radiographics. 2009;29:1073–83.CrossRefPubMed
20.
Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage. 2009;38:341–9.CrossRefPubMed
21.
Garofalo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol. 2006;32:682–5.CrossRefPubMed
22.
Facchiano E, Scaringi S, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2008;34:154–8.CrossRefPubMed
23.
Patriti A, Cavazzoni E, Graziosi L, et al. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech. 2008;18:426–8.CrossRefPubMed
24.
Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009;100:331–4.CrossRefPubMed
25.
Ba MC, Cui SZ, Lin SQ, et al. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 2010;16:1901–7.CrossRefPubMedPubMedCentral
26.
Antos F, Dytrych P, Vitek P, Ryska O, Marvan J, Serclovla Z. Malignant ascites–optional management using hyperthermic peroperative chemotherapy (HIPEC). Rozhl Chir. 2010;89:237–41.PubMed
27.
Ba MC, Long H, Cui SZ, et al. Multivariate comparison of B-ultrasound-guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites. Surg Endosc. 2013;27:2735–43.CrossRefPubMed
28.
Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21:1474–9.CrossRefPubMed
29.
Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4:87–95.CrossRefPubMedPubMedCentral
30.
World Health Organization. Cancer pain relief: with a guide to opioid availability, 2nd ed. Geneva: World Health Organization; 1996. p. 12–5.
31.
Cauley CE, Panizales MT, Reznor G, et al. Outcomes after emergency abdominal surgery in patients with advanced cancer: opportunities to reduce complications and improve palliative care. J Trauma Acute Care Surg.2015;79:399–406.CrossRefPubMedPubMedCentral
32.
Pameijer CR, Mahvi DM, Stewart JA, Weber SM. Bowel obstruction in patients with metastatic cancer: does intervention influence outcome? Int J Gastrointest Cancer. 2005;35:127–33.CrossRefPubMed
33.
Smith TJ, Temin S, Alesi ER, et al. American society of clinical oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30:880–7.CrossRefPubMed
34.
35.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2012;363:733–42.CrossRef
Metadata
Title
Palliative Management of Peritoneal Metastases
Authors
Laura A. Lambert
Jason Wiseman
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6335-7

Other articles of this Issue 8/2018

Annals of Surgical Oncology 8/2018 Go to the issue

Thoracic Oncology

Clinical Complete Response After Neoadjuvant Therapy for Esophageal Cancer: What’s Lurking Under the Surface?

Pancreatic Tumors

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67

Bone and Soft Tissue Sarcomas

Strategic Delay: Histology- and Biology-Driven Decision-Making in Recurrent Retroperitoneal Sarcoma

Gastrointestinal Oncology

Multicenter Study of Presentation, Management, and Postoperative and Long-Term Outcomes of Septegenerians and Octogenerians Undergoing Gastrectomy for Gastric Cancer

Breast Oncology

Positive Nipple Margin After Nipple-Sparing Mastectomy: An Alternative and Oncologically Safe Approach to Preserving the Nipple–Areolar Complex

Colorectal Cancer

Nationwide Heterogeneity in Hospital-Specific Probabilities of Rectal Cancer Understaging and Its Effects on Outcomes